Background The objective of this article is to summarize the published literature concerning
the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently …

Venous thrombosis is a leading cause of morbidity and mortality in industrialized countries,
especially in the elderly. Many risk factors have been identified for venous thrombosis that …

Background—Rivaroxaban and dabigatran are new oral anticoagulants that specifically
inhibit factor Xa and thrombin, respectively. Clinical studies on the prevention and treatment …

Platelet activation and subsequent thrombus formation at sites of vascular injury is crucial for
normal hemostasis, but it can also cause myocardial infarction and stroke. The initial capture …

Aim This study investigated the effects of hepatic impairment on the pharmacokinetics and
pharmacodynamics of a single dose of rivaroxaban (10 mg), an oral, direct F actor X a …

Venous thromboembolism (VTE) is a leading cause of morbidity and mortality worldwide.
However, the mechanisms by which clots are formed in the deep veins have not been …

The use of warfarin, the most commonly prescribed oral anticoagulant, is being questioned
by clinicians worldwide due to warfarin several limitations (a limited therapeutic window and …

Unlike traditional anticoagulants, the more recently developed agents rivaroxaban,
dabigatran and apixaban target specific factors in the coagulation cascade to attenuate …

Several new oral anticoagulants such as rivaroxaban (which targets Factor Xa) and
dabigatran etexilate (which targets thrombin) are in advanced stages of clinical development …

Background: Rivaroxaban represents a selective direct inhibitor of activated coagulation
factor X (FXa) having peroral bioavailability and prompt onset of action. Objective: The …